BDR Pharma launches generic Pazopanib to treat these diseases

Kidney cancers rank about 20th on the list of all types of cancers according to incidence and prevalence, in India

149
Medicine Tablets
Picture: Unsolash

Last Updated on December 22, 2021 by The Health Master

With a vision to make globally available high-cost medicines accessible to Indian patients at affordable prices, BDR Pharma, which has always been a key player, announced the launch of generic Pazopanib in the Indian market, under the brand name Bdpazo.

It will be available in two strengths – 200 mg and 400 mg – packed in bottles of 30 tablets each.

Pazopanib is a second-generation multi-targeted tyrosine kinase inhibitor and antineoplastic agent used in the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma in patients with prior chemotherapy.  

Kidney cancers rank about 20th on the list of all types of cancers according to incidence and prevalence, in India. Its key causes include genetic syndromes, long-standing uncontrolled hypertension, and, to some extent, smoking.

According to Raheel Shah, director – business development, BDR Pharmaceuticals, this launch further enhances the kidney cancer treatment portfolio in the BDR product basket with the addition of generic Pazopanib with the brand names Bdpazo 200 and Bdpazo 400.  

BDR is proud to have led the way for an accessible treatment option for renal cell carcinoma patients that may alleviate the financial burden for Indian patients. BDR Pharma has been working diligently to improve the supply of accessible, high-quality medicines to Indian patients.

With its availability in tablet form, it makes it easier and more convenient for such patients to continue the treatment. With generic Pazopanib and with proven median progression free survival and better tolerability, renal cell carcinoma & soft tissue sarcoma patients will now have access to this medicine at an affordable cost that could significantly extend their lives.

Those closely following global pharma’s’ fight against the notorious coronavirus will have heard of BDR Pharmaceuticals. The Mumbai-based pharmaceutical company grabbed headlines throughout 2020-2021 for being a front runner in the race to manufacture drugs that fight the Coronavirus.

When there was an urgent need for a self-reliant supply of the virus-fighting drugs in the country, the home-based company played a significant role in manufacturing Covid-19 drugs and made a whole basket of such drugs available for the Indian patients.

The drug will be available in the form of tablets.

Dr Reddy’s launches drug to treat high Blood Pressure, Heart failure

India’s first generic drug for cancer treatment launched

BDR Pharma launches Antibiotics to treat these infections

Natco Pharma launches FDC Trifluridine & Tipiracil first time in India

MSN Labs launches Vigabatrin Powder for the treatment of Epilepsy

A portable Hydrogen inhaler launched: Dual-use technology

Haryana is the best state for setting up Pharma Industries: HM

USFDA gives nod to Cipla for Lanreotide injection

CDSCO panel’s nod to Sun Pharma for Rosuvastatin Sprinkle Capsules

USFDA gives Orphan Drug Designation to Zydus for malaria treatment

USFDA relaxes restriction on Abortion Pill

Medical Devices: Current scenario and need of the hour

Govt notifies NIB, Noida as CDL to test Covid-19 vaccines

FDA Haryana and police unearthed a unit manufacturing spurious cosmetics

Recruitment of 87 Drug Inspectors put on hold in Maharashtra

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner